Strongyloidiasis Hyperinfection Syndrome in COVID-19 Positive Migrants Treated with Corticosteroids.
J Immigr Minor Health
; 24(6): 1431-1434, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2128926
ABSTRACT
The aim of this study is to highlight the potentially fatal risk of Strongyloidiasis Hyperinfection Syndrome for hospitalized immigrant patients with moderate to severe COVID-19 disease and undiagnosed Strongyloidiasis. We reviewed electronic medical records of immigrants from 2010 to 2022 and extracted the number of patients with eosinophilia, strongyloidiasis and COVID-19 infection, outpatient and hospitalized. While 885 outpatients were diagnosed with eosinophilia, only 356 (40.2%) were tested for strongyloidiasis and 160 (44.9%) yielded a reactive serology. COVID-19 infection was reported in 6,412 patients. 1135 (17.7%) of these patients sought hospital care. Patients with undiagnosed strongyloidiasis are at risk for a potentially fatal parasitosis if treated with systemic corticosteroids for COVID-19. This supports clinical guidelines in hospital settings for those with severe COVID-19. Strongyloidiasis should be considered by taking a thorough travel or migration history and testing before giving immunosuppressive drugs.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Strongyloidiasis
/
Transients and Migrants
/
Strongyloides stercoralis
/
Eosinophilia
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
J Immigr Minor Health
Journal subject:
Social Sciences
/
Public Health
Year:
2022
Document Type:
Article
Affiliation country:
S10903-022-01386-w
Similar
MEDLINE
...
LILACS
LIS